This report represents a unique collaborative effort among international specialists in the field of oncology and reproductive medicine. An evidence based approach was used to develop recommendations regarding surveillance for premature ovarian insufficiency in female childhood, adolescent and young adult cancer survivors. In particular, because females exposed to specific gonadotoxic treatments including alkylating agents and ovarian radiation are at highest risk for ovarian insufficiency, these survivors should be monitored closely before and after puberty. The focus of monitoring should be on growth, pubertal development, assessment of menstrual function and measurement of serum FSH and Estradiol. The authors concluded that AMH may be a reasonable adjunct for assessing ovarian reserve in women at least 25 years of age. Referral to a reproductive specialist is strongly recommended for females with premature ovarian insufficiency for consideration of hormone replacement therapy, and for post-pubertal females concerned about their future fertility. While there are limited data on fertility preservation in cancer survivors remote from treatment, fertility preservation such as egg freezing may be an option for survivors who plan to delay childbearing. Counseling cancer survivors about the reproductive impact of cancer therapies may improve health, quality of life, and expand the reproductive options for young cancer survivors. This guideline provides clinicians with important recommendations to improve the health and wellbeing of survivors.
Recently the American Society for Reproductive Medicine issued a new guideline assessing the impact of fertility drugs on the risk of cancer in women. This guideline was developed after a comprehensive literature search and grading the available data on this topic. The committee concluded that data...
The contents of the Oncofertility Consortium Blog are for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
965 Wilson Road, Room A626B
East Lansing, MI 48824-1316
Phone: 1 (517) 884 6434
Email: oncofert@msu.edu
NOTICE:
Ownership of this website has been transferred from Northwestern University to Michigan State University. Please note that some site information may be inaccurate while adjustments to reflect this organizational change are made.